Search

CN-121987777-A - Application of PD-L1 single domain antibody in preparation of hair growth promoting or alopecia preventing and treating preparation

CN121987777ACN 121987777 ACN121987777 ACN 121987777ACN-121987777-A

Abstract

The invention discloses application of a PD-L1 single domain antibody in preparation of a preparation for promoting hair growth or preventing and treating alopecia, belongs to the technical field of biological medicines, and particularly discloses application of the PD-L1 single domain antibody in regulation and control of cytokine IL-6 and Leptin expression so as to activate JAK-STAT signal paths, and provides a new preparation source for treating non-scarring alopecia.

Inventors

  • CHEN JINLIN
  • CHEN JIANMING
  • YANG MINGHAN
  • CHENG YUNYING
  • CHEN LIN

Assignees

  • 闽江学院

Dates

Publication Date
20260508
Application Date
20251226

Claims (5)

  1. Use of a pd-L1 single domain antibody in the preparation of a formulation for promoting hair growth or preventing hair loss.
  2. 2. The method of claim 1, wherein the PD-L1 single domain antibody has the effect of regulating the expression of cytokines IL-6 and Leptin, thereby activating the JAK-STAT signal pathway.
  3. 3. The method of claim 1, wherein the PD-L1 single domain antibody exhibits high expression in hair matrix cells and hair shafts of hair follicles from stage II to stage IV.
  4. 4. The method according to claim 1, wherein the preparation is a solvent and is administered by subcutaneous injection, the PD-L1 single-domain antibody is subcutaneously injected at a dose of 5 mg/kg, and the concentration of the PD-L1 single-domain antibody is not less than 1 mg/mL.
  5. 5. A preparation for promoting hair growth or preventing and treating alopecia is characterized by comprising PD-L1 single domain antibody.

Description

Application of PD-L1 single domain antibody in preparation of hair growth promoting or alopecia preventing and treating preparation Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of a PD-L1 single domain antibody in preparation of a preparation for promoting hair growth or preventing and treating alopecia. Background Alopecia is classified into cicatricial alopecia and non-cicatricial alopecia. Scarring alopecia is a permanent alopecia, the essence of which is that normal hair follicle tissue is replaced by connective tissue, resulting in permanent loss of hair follicle function and inability to regenerate new hair. Non-scarring alopecia is a type of alopecia in which the hair follicle structure is not permanently destroyed, and is the most common and curable type of alopecia clinically, and in general, hair can be regrown as long as intervention is in time. The growth cycle of hair follicles can be divided into three phases, namely a growth phase, a retrograde phase and a resting phase. Common types of non-scarring hair loss include seborrheic alopecia, alopecia areata, and telogen effluvium. Seborrheic alopecia commonly called androgenetic alopecia is caused by shortened anagen phase, advanced anagen phase and prolonged telogen phase of susceptible hair follicles under the action of androgens (dihydroxytestosterone), gradual micromation of hair follicles, alopecia areata is caused by autoimmune disorder, T lymphocyte attack on hair follicles, hair follicle development cannot normally enter anagen phase, telogen phase alopecia is caused by malnutrition, endocrine disorder and other reasons, and hair follicle growth cycle enters telogen phase in advance. Therefore, the main cause of the non-scarring alopecia is caused by the fact that the hair follicles are stressed by various types, so that the number of hair follicles in anagen phase is reduced, and the number of hair follicles in telogen phase is increased. Therefore, one of the keys to cure non-scarring alopecia should be to promote the telogen follicle to re-enter anagen phase, restore the regenerative capacity of the follicle, improve the microenvironment of the follicle, and maintain the continued growth of the hair shaft. Currently, medicines approved for treating non-scarring alopecia are very limited in market, minoxidil is an external medicine for treating alopecia, can prolong the growth period of hair, shorten the retrograde period and the telogen period, enable hair follicles to enter a new growth stage more quickly, easily cause increase of non-target area hair in the using process, gradually disappear the treatment effect after stopping taking, finasteride is an oral medicine approved for treating male seborrheic alopecia, and has good continuous use effect, but has more adverse reactions after taking, often causes side effects of sexual dysfunction, male breast abnormal development and the like, oral contraceptive medicines such as levonorgestrel, norgestrel and the like, are approved for treating female seborrheic alopecia, need to take continuously for at least 12 months, often cause irregular menstrual period, mood fluctuation and the like, and baritenib is an oral JAK inhibitor, is obtained for treating alopecia, and has good long-term curative effect and safety. In addition, no medicine for treating non-scarring alopecia exists in the current commercial market. Therefore, there is a lack of drugs and products for treating alopecia that provide durable therapeutic effects and ensure long-term safety for patients. PD-L1 (programmed death ligand-1) is an immune checkpoint protein with immunoregulatory function. PD-L1 monoclonal antibodies are well known antitumor drugs and are used in the immunotherapy of various tumor diseases. PD-L1 single domain antibodies have not been reported in drug development for treating alopecia. Disclosure of Invention The invention aims to provide application of PD-L1 single domain antibody in preparing a preparation for promoting hair growth or preventing and treating alopecia, and develop a medicament for promoting hair growth or preventing and treating alopecia. The invention provides application of PD-L1 single domain antibody in preparing a preparation for promoting hair growth or preventing and treating alopecia. The nucleotide sequence of the PD-L1 single-domain antibody is shown as SEQ ID NO.1, the amino acid sequence of the PD-L1 antibody is shown as SEQ ID NO.2, and the PD-L1 single-domain antibody is disclosed in a patent with publication number CN 112940121A. Further, PD-L1 single domain antibodies play a role in regulating the expression of cytokines IL-6 and Leptin, thereby activating JAK-STAT signaling pathway. Further, PD-L1 single domain antibodies exhibit high expression in hair matrix cells and hair shafts of phase II to phase IV hair follicles. Furthermore, the preparation is a solvent and is administrated in a